Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs

Abstract Background Indication for treatment with osimertinib after first/second generation (1/2G) epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) resistance depends on T790M mutation detected by rebiopsy. The aim of our study was to analyze the data on clinical practice at our...

Celý popis

Podrobná bibliografie
Hlavní autoři: Taira Ninomaru, Akito Hata, Chiyuki Kokan, Hideaki Okada, Hirotaka Tomimatsu, Jun Ishida
Médium: Článek
Jazyk:English
Vydáno: Wiley 2021-03-01
Edice:Thoracic Cancer
Témata:
EGFR‐mutant NSCLC
EGFR‐TKI
osimertinib
rebiopsy
T790M
On-line přístup:https://doi.org/10.1111/1759-7714.13822

Internet

https://doi.org/10.1111/1759-7714.13822

Podobné jednotky